Cartesian Therapeutics, Inc.’s RNAC share price has surged by 8.40%, which has investors questioning if this is right time to sell.

Shares of Cartesian Therapeutics climbed after the company announced positive results in a phase 2b trial of its lead cell-therapy candidate. The stock was up 8.3% to $15.60 in morning trading Tuesday ...

Cartesian Therapeutics, Inc.’s RNAC share price has dipped by 18.96%, which has investors questioning if this is right time ...